EGFR and non-small cell lung carcinoma: In addition, CIB2 holds potential as a therapeutic target for overcoming epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance in non-small-cell lung cancer (NSCLC).